Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1221-1229

  Babij, Rachel ^a   Perumal, Jai S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alemtuzumab; Comparative efficacy; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOIMMUNE DISEASE; BURKITT LYMPHOMA; CHILL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; FEVER; GOODPASTURE SYNDROME; GRAVES DISEASE; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; MELANOMA; MEMBRANOUS GLOMERULONEPHRITIS; MOUTH INFECTION; MULTIPLE SCLEROSIS; MYALGIA; NEUTROPENIA; PANCYTOPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; RELAPSE; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84930203098     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S60518     Document Type: Review

References (51)

1. Vukusic S, Confavreaux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20(3): 369-374.
2. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112: 133-146.
3. Jeffrey S. FDA approval for alemtuzumab (Lemtrada) in MS. Medscape Medical News, 2014. Available from: http://www.medscape.com/viewarticle/834994. Accessed April 9, 2015.
4. Sorensen P. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014;27(3):246-259.
5. Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care. 2013; 19(17 Suppl):343-354.
6. Perumal J, Khan O. Emerging disease-modifying therapies in multiple sclerosis. Curr Treat Options Neurol. 2012;14(3):256-263.
7. Cree BA. 2014 Multiple sclerosis therapeutic update. Neurohospitalist. 2014;4(2):63-65.
8. Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care. 2013; 19(17 Suppl):321-333.
9. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1): 14-24.
10. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66(4):460-471.
11. Freedman MS. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon beta therapy. Eur J Neurol. 2013;21(3):377-387.
12. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98-108.
13. Confavreaux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343-369.
14. Wingerchuk D, Carter J. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-240.
15. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131 Pt 3:808-817.
16. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412-1420.
17. Morgen K, Jeffries NO, Stone R, et al. Ring-enhancement in multiple sclerosis: marker of disease severity. Mult Scler. 2001;7(3):167-171.
18. Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73(7):625-650.
19. National Multiple Sclerosis Society. Medications approved for the treatment of multiple sclerosis. Available from: http://www.nationalmssociety.org/Treating-MS/Medications. Accessed April 9, 2015.
20. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2014;141(1):123-131.
21. Coles A. Alemtuzumab treatment of multiple sclerosis. Semin Neurol. 2013;33(1):66-73.
22. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell mediated disease in MS? Ann Neurol. 2010;67(4): 452-461.
23. Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26(25):3644-3653.
24. Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 2014;83(1): 87-97.
25. Jones D, Goldman M. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Expert Rev Clin Immunol. 2014;10(10):1281-1291.
26. Hartung H, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):22-34.
27. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133 Pt 8:2232-2247.
28. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613-623.
29. Elliot C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain. 2012;135(6):1819-1833.
30. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579-582.
31. Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E. Immunoadsorption in steroid-refractory multiple sclerosis: clincial experience in 60 patients. Atheroscler Suppl. 2013;14(1):167-173.
32. Leussink VI, Lehmann HC, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab: evidence for disease heterogeneity. J Neurol. 2008;255(9):1436-1438.
33. Stüve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005;62(10):1620-1623.
34. Stüve O, Leussink VI, Fröhlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66(2):259-261.
35. Thompson S, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99-105.
36. Polman CH, O'Connor PW, Havrdova E, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-891.
37. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
38. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 402-415.
39. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365(14):1293-1303.
40. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9): 2297-2305.
41. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
42. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta-1a as a first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012; 380(9856):1819-1828.
43. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856): 1829-1839.
44. Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013;7: 131-138.
45. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis: the CAMMS223 trial investigators. N Engl J Med. 2008; 359(17): 1786-1801.
46. Coles A, Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon b-1a at 5-year follow up of CAMMS223 trial. Neurology. 2012;78(14):1069-1078.
47. Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol. 2010; 185(1):763-768.
48. Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208-215.
49. Kousin-Ezewu O, Coles A. Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Ther Adv Chronic Dis. 2013;4(3): 97-103.
50. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med. 2008;359(7): 768-769.
51. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-340.